James Kochenderfer

James Kochenderfer

National Institutes of Health - Bethesda / United States
Medical and Health Sciences / Hematology
AD Scientific Index ID: 4397322
person_outline James Kochenderfer's MOST POPULAR ARTICLES
1-) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial The Lancet 385 (9967), 517-528, 2015
2-) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells Blood, The Journal of the American Society of Hematology 119 (12), 2709-2720, 2012
3-) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood, The Journal of the American Society of Hematology 116 (20), 4099-4102, 2010
4-) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma New England Journal of Medicine 380 (18), 1726-1737, 2019
5-) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myelomaN Raje, J Berdeja, YI Lin, D Siegel, S Jagannath, D Madduri, M Liedtke, ...New England Journal of Medicine 380 (18), 1726-1737, 201916542019